A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants

Exclusion Criteria9

• Participants who meet any of the following criteria will be excluded from the study:
• Presence of EGFR gene mutation;
• Pathological diagnosis of small cell lung cancer or mixed tumors with small cell components, large cell neuroendocrine carcinoma (LCNEC), or sarcomatoid tumors;
• Have previously received any of the following treatments:
• Have received \> 4 cycles of adjuvant chemotherapy. Prior neoadjuvant therapy. Major surgery within 4 weeks prior to randomization (including surgery for the primary neoplasm, but excluding vascular access procedures), or expected to undergo major surgery during the study.
• Use of Chinese herbal medicine with anti-tumor indications within 14 days prior to randomization.
• Use of growth factor support therapy or have received a transfusion within 14 days prior to randomization.
• Prior treatment with anti-PD-1, anti-PD-L1/2, anti-CD137, CTLA-4 modulators, or any other immunomodulatory agents.
• Severe acute or chronic infection, including any active infection requiring systemic anti-infective therapy within 2 weeks prior to randomization;